Biotest AG VZ Stock
Price
Target price
€30.00
€30.00
-3.310%
-1.0
-3.310%
-
06.06.25 / Tradegate
WKN: 522723 / Name: Biotest / Stock / Pharmaceuticals / Small Cap /
We currently do not receive price updates for this security
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Biotest
sharewise wants to provide you with the best news and tools for Biotest, so we directly link to the best financial data sources.
Financials
News
EQS-News: Biotest obtains approval for new human fibrinogen Prufibry® in Germany
EQS-News: Biotest obtains approval for new human fibrinogen Prufibry® in Germany
EQS-News: Biotest AG: Extraordinary general meeting convened again at the request of Grifols S.A.
EQS-News: Biotest AG: Extraordinary general meeting convened again at the request of Grifols S.A.
EQS-News: Biotest AG: Cancellation of the extraordinary general meeting on 28 October 2025
EQS-News: Biotest AG: Cancellation of the extraordinary general meeting on 28 October 2025
EQS-News: Biotest’s Yimmugo® launches in the United States
EQS-News: Biotest’s Yimmugo® launches in the United States
EQS-News: Biotest AG: Extraordinary general meeting convened at the request of Grifols S.A.
EQS-News: Biotest AG: Extraordinary general meeting convened at the request of Grifols S.A.
EQS-News: Biotest AG receives a request from Grifols S.A. to convene an extraordinary general meeting
EQS-News: Biotest AG receives a request from Grifols S.A. to convene an extraordinary general meeting
EQS-News: Biotest AG: Annual General Meeting approves dividend distribution
EQS-News: Biotest AG: Annual General Meeting approves dividend distribution
EQS-News: Biotests’ positive fibrinogen phase III trial results published in The Lancet’s eClinicalMedicine
EQS-News: Biotests’ positive fibrinogen phase III trial results published in The Lancet’s eClinicalMedicine
EQS-Adhoc: Biotest AG: Delisting of Biotest shares from the Frankfurt Stock Exchange with effect from 6 June 2025
EQS-Adhoc: Biotest AG: Delisting of Biotest shares from the Frankfurt Stock Exchange with effect from 6 June 2025
EQS-Adhoc: Biotest AG: Change of the Chief Executive Officer (CEO) of Biotest AG
EQS-Adhoc: Biotest AG: Change of the Chief Executive Officer (CEO) of Biotest AG